MentalHealthDaily

Prader-Willi Syndrome: New Treatments & Medications in Development & Clinical Trials (2023)

Prader-Willi Syndrome (PWS) is a rare genetic condition marked by a diverse range of physical, mental, and behavioral challenges. Characterized by uncontrolled appetite and obesity, cognitive impairments, and social and behavioral issues, PWS presents unique challenges for patients and caregivers. Highlights: Prevalence and Genetics: PWS affects approximately 1 in 20,000 live births, caused by errors …

Dextromethorphan-Bupropion (Auvelity) for Depression: Clinical Trial Data for the New Rapid-Acting Antidepressant

by GLOOM

Major depressive disorder (MDD) is a significant global health concern, affecting over 280 million people worldwide. While numerous pharmacological options exist, challenges remain in achieving timely, robust, and sustained antidepressant response. Dextromethorphan-bupropion is a novel oral antidepressant recently approved by the FDA for MDD in adults that may address some of these unmet needs. Key …

9 New Anxiety Medications (2018): Drugs In Clinical Trials

by GLOOM

Collected data from the Anxiety and Depression Association of America (ADAA) suggests that upwards of 40 million adults are affected by anxiety, or approximately 18% of the United States population. Among the 40 million adults who are affected by anxiety, it is estimated that approximately: 19 million suffer from specific phobias; 15 million suffer from …

Vraylar (Cariprazine) Approved For Schizophrenia & Bipolar Disorder

by GLOOM

Vraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder. In clinical trials, the drug was referenced as “RGH-188” – containing Cariprazine as the primary active ingredient. The drug had completed Phase III clinical trials in 2012, and was pending FDA approval for …

6 New Autism Medications (2015): Drugs In Clinical Trials

by GLOOM

Autism spectrum disorder (ASD) is a severe neurodevelopmental disorder that significantly affects behavior, cognitive function, and social skills. Those with the disorder often engage in repetitive behaviors, suffer from low intelligence, and have severe difficulty verbalizing their thoughts. In fact, a subset individuals with autism are incapable of any verbal communication and resort to gesturing …

3 New Narcolepsy Medications (2015) In Clinical Trials

by GLOOM

Narcolepsy is a neurological disorder associated with the brain’s inability to regulate sleep-wake cycles (and the circadian rhythm). As a result, individuals diagnosed with narcolepsy often experience excessive daytime sleepiness and may fall asleep unexpectedly. Some have suggested that the excessive daytime sleepiness stemming from narcolepsy is akin to how a normal person feels if …

3 New Bipolar Medications (2015): Drugs In Clinical Trials

by GLOOM

Bipolar disorder is a condition characterized by cyclical mood swings, transitioning from depression to mania (or hypomania). For a period of time, an individual with bipolar disorder will experience debilitating bouts of depression – and often unexpectedly, their entire neurophysiology will shift to facilitate a state of mania (elevated mood). Diagnostically, there are multiple types …